Regimen showed significant improvement in overall survival in trial versus Sutent
Drug is first and only approved specific reversal agent for a novel oral anticoagulant
Test performed in the primary care setting may improve access to screening
Researchers found no association between clinical value and cost
Lenses automatically darken in bright light
Agent is now approved for the maintenance treatment of recurrent disease regardless of BRCA status
Agency aims to ensure women are properly informed of the risks
Approach would allow for drug testing in patients before clinical symptoms appear
Product would be the first lotion to combine halobetasol and tazarotene in one formulation
Monotherapy significantly improved overall survival as first-line therapy in certain NSCLC patients

P&T April 2018
Table of Contents


Health Systems Take Matters Into Their Own Hands
Generic shortages are draining hospital resources throughout the U.S. and in some cases imperiling inpatient treatment. The author considers the FDA’s performance and describes the approach some health systems are taking to create a solution.
Staying up to date with evolving pharmacotherapies is important to providing optimal therapies to patients. The authors present available evidence to support the role of novel and existing agents in treating type-2 diabetes.
The authors briefly review febrile neutropenia, describe risk assessment tools, and discuss treatment and prophylactic options for this serious complication.
Pipeline Plus
Despite failures in late-phase trials, the pipeline of medications for Alzheimer’s disease is robust as companies hope to be the first to bring an effective therapy to market. We review several investigational agents in late-stage development.


Medication Errors
Harm and death associated with methotrexate errors
Prescription: Washington
CMS consideration of rebate overhaul elicits strong opinions
Approvals, new indications, regulatory activities, and more
Netarsudil ophthalmic solution (Rhopressa) for the reduction of elevated intraocular pressure; ertugliflozin (Steglatro) for adults with type-2 diabetes; and lutetium lu 177 dotatate (Lutathera) for certain gastroenteropancreatic neuroendocrine tumors
Drug Forecast
Plecanatide (Trulance) for chronic idiopathic constipation and irritable bowel syndrome with constipation